Home>Topics>Stocks>Roche Holding AG ADR

Roche Holding AG ADR RHHBY

  1. All
  2. Commentary
  3. Headlines
    1. New Link Genetics and Genentech team up in cancer immunotherapy

      Headlines

      Mon, 20 Oct 2014

      New Link Genetics (NASDAQ: NLNK ) and Roche's Genentech ( OTCQX: RHHBY ) enter into an exclusive worldwide license agreement for the development of New Link's IDO pathway inhibitor , NLG919. Under

    2. Members of Big Pharma to square off at breast cancer meeting

      Headlines

      Fri, 17 Oct 2014

      Roche ( OTCQX: RHHBY ) and Merck (NYSE: MRK ) are set to present data from their respective immunotherapy drugs for the treatment of triple negative

    3. Eylea beats Avastin and Lucentis in comparative study

      Headlines

      Fri, 17 Oct 2014

      improvement in mean change in best-corrected visual acuity from baseline at week 52 compared to both Genentech's ( OTCQX: RHHBY ) Avastin (bevacizumab) and Lucentis (ranibizumab) injection. The was the study's primary endpoint. The mean number

    4. Roche Holding's ( RHHBY ) CEO Severin Schwan on Q3 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 16 Oct 2014

      By SA Transcripts : Roche Holding Ltd ADR ( OTCQX: RHHBY ) Q3 2014 Earnings Conference Call October 16, 2014, 08:00 AM ET Executives Severin Schwan - Chief Executive Officer Dan O

    5. Diplomat Pharmacy to distribute Esbriet, shares jump

      Headlines

      Thu, 16 Oct 2014

      Recent IPO Diplomat Pharmacy ( DPLO +12.1% ) jumps as traders anticipate upside revenue from its distribution of Roche's ( OTCQX: RHHBY +0.2% ) just-FDA-approved Esbriet (pirfenidone). Turnover is only 37K shares, however. 1 comment!

    6. Roche sales up 5% ytd

      Headlines

      Thu, 16 Oct 2014

      Roche ( OTCQX: RHHBY ) financial results ytd through Q3 (Millions of CHF): Group Sales: 34,757 (-0.3%); Pharmaceuticals: 26,965

    7. Good day for sufferers of IPF

      Headlines

      Wed, 15 Oct 2014

      fibrosis have reason to cheer today. The FDA approves two new drugs to treat the disease. The agency approves Roche's ( OTCQX: RHHBY -0.5% ) Esbriet (pirfenidone) ahead of its November 23, 2014 PDUFA date under its Fast Track, Breakthrough Therapy and

    8. My Vision Of What The 'Perfect Retirement Portfolios For Dummies' Might Look Like

      Headlines

      Sun, 12 Oct 2014

      By Factoids : As far as I can tell from my web searches, I appear to be the person who coined the hyperbole "There are no bad stocks, only bad portfolios." That statement needs some explaining. This is an article on portfolios - especially equity income producing retirement portfolios that will ...

    9. Ohr Pharamceuticals: Stay On The Sidelines

      Headlines

      Fri, 10 Oct 2014

      By Ugly Duckling : Clinical Results Investors in Ohr Pharmaceuticals (NASDAQ: OHRP ) were taken for quite a ride on the heals of the release of interim results of the OHR-102 clinical trial. The stock gyrated as investors tried to balance the failure of the trial to attain its stated endpoint with

    10. Roche to report on October 16

      Headlines

      Thu, 9 Oct 2014

      Roche ( OTCQX: RHHBY -1.5% ) will report Q3 results on October 16 at 7:00 am CEST/1:00 am ET/10:00 pm PT (evening before). The conference call will begin at 2:00 pm CEST/8:00 am ET/5:00 am PT. Post your comment!

    « Prev12345Next »
    Content Partners